Symposia Schedule of Events

Please note some presentations are requesting pre-registration. Those links are provided in the session listings below if applicable.

Tuesday, September 8, 2020

9–10 am EST

Learn More About an FDA-Approved Treatment for Metastatic Triple-Negative Breast Cancer
Tiffany M Bruno, APRN, MSN, AGACNP-BC Nurse Practitioner, Breast Oncology Texas Oncology, Baylor Sammons Cancer Center
Presented by Immunomedics

NERLYNX® (neratinib) for Patients with HER2+ Breast Cancer: Strategies and Support Tools to Achieve Durable Therapy
Puma Biotechnology
Please join us for this educational program on Tuesday, September 8th at 9:00 AM to learn more about NERLYNX® (neratinib) for HER2+ Breast Cancer including how to anticipate and mitigate TKI adverse events. Our nurse oncology expert will share data on NERLYNX and strategies to equip you and your practice to support these high-risk patients on TKI therapy.

5–6 pm EST

Advances in Hemophilia A: Coordinating Care Through Effective Communication and Therapy Selection
1 Contact Hour
This continuing nurse education activity is provided by Vindico Medical Education.
Join Regina B. Butler, RN-BC; James E. Munn MS, BS, BSN, RN-BC; and Kerry Hansen RN, BSN on Tuesday, September 8 at 5 PM EDT for a CNE Virtual Symposium with live Q & A. They will assess the latest evidence regarding treatments for patients with hemophilia A, provide guidance on identifying patients without factor VIII inhibitors who may benefit from newer treatment options, and discuss strategies to promote shared decision-making and improve patient satisfaction.

New Strategies for Multiple Myeloma Care: Case Studies for Nurses
1.5 Contact Hours
International Myeloma Foundation
REGISTER HERE: https://imf-ons.myeloma.org/
This activity is supported by educational grants from Bristol Myers Squibb (formerly Celgene); GlaxoSmithKline; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; Karyopharm Therapeutics Inc.; Oncopeptides, Inc.; and Takeda Oncology.

Multiple myeloma care is rapidly evolving with new agents and combinations, new testing, and risk-adapted treatment strategies. Four highly experienced nurses will share their expertise during this 1.5 CNE symposium (3 sessions of 0.5 CNE) while using real-life patient case scenarios to focus on symptom management, infection control, and nursing implications. The participants can take part in a single session, two sessions, or the entire symposium. Free downloadable tools and resources are provided.

**Important Evidence-Based Changes in the Metastatic Castration-Sensitive Prostate Cancer (mCSPC) Treatment Landscape**

Astellas

Join us to learn about
- An overview of the mCSPC disease state
- The efficacy and safety profile of XTANDI in mCSPC
- XTANDI dosing and administration

**Thursday, September 10, 2020**

9–10 am EST

**CAR T-CELL THERAPY: A ROAD MAP FOR NURSES**

1 Contact Hour

**REGISTER HERE:** [www.LLS.org/ONSCART2020](http://www.LLS.org/ONSCART2020)

This session is provided by The Leukemia & Lymphoma Society with support from Bristol Myers Squibb Company, Kite, A Gilead Company and Novartis Pharmaceuticals Corporation

Nurses from three cancer centers will discuss the nurse’s role in preparing patients and caregivers for the CAR T-cell treatment process, assessment, monitoring for and managing side effects, and communication with the patient’s community healthcare team to transition patient care. Following a patient from initial treatment discussion, symposium attendees will be able to provide feedback on patient care for the case, in this interactive session. With CAR T therapy and follow-up care expanding beyond the major centers, nurses are essential members of the treatment team.

**Treatment of patients in newly diagnosed multiple myeloma**

**Patient adherence and dose modifications in response to adverse events**

BMS Multiple Myeloma

This program will share information about a treatment option for newly diagnosed multiple myeloma including the impact of multiple myeloma on patients, dose modifications for consideration due to adverse events, and approaches to keep patients on therapy.
Putting NSCLC to the Test: Oncology Nurse Perspectives in the Era of Precision Medicine

1 Contact Hour

Presented by Creative Educational Concepts, Inc. (CEC) and supported through an independent educational grant from AstraZeneca.

Let us buy your lunch after the meeting! Receive a GrubHub credit for attending this presentation and receive 1.0 ANCC credit. Participants will gain an appreciation of the latest advances in non-small cell lung cancer (NSCLC), including the nurse’s role in comprehensive biomarker testing strategies and biomarker-driven treatment approaches. Expert faculty will reflect on the lung cancer tumor board, with emphasis on the appropriate selection of targeted therapy based on patient- and biomarker-specific factors in oncogenic driver mutations. This presentation will also explore strategies to improve communication between nurses and patients/caregivers in an effort to promote shared decision-making, reduce adverse events, and improve adherence. In Partnership with LUNGevity Foundation

5–6 pm EST

*BRAFTOVI® (encorafenib) + MEKTOVI® (binimetinib); For the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation as detected by an FDA-approved test*

Array BioPharma

Tuesday, September 15, 2020

9–10 am EST

*CAR T Cell Therapy: The Science and Patient Journey*

Bristol Myers-Squibb CAR-T

Learn more about the potential of CAR T cell therapy. This presentation will help you understand the science behind this novel immunotherapy and its ability to fight certain cancers. You’ll learn about the CAR T cell therapy patient journey, as well as the multidisciplinary treatment team that supports them. The presentation will close with how to monitor and manage select side effects of treatment.

5–6 pm EST

*Introducing a New Treatment Option for Patients With Previously Treated Metastatic Small Cell Lung Cancer (SCLC)*
Jazz Pharmaceuticals (via Area23 on Hudson)

REGISTER HERE: https://www.surveymonkey.com/r/JazzSymposium

Join us for this expert-led program where we will explore:

- An overview of unmet needs in SCLC
- Current treatment guidelines for SCLC
- Efficacy and safety findings from a study of an FDA-approved treatment for previously treated metastatic SCLC
- Considerations for dosing, administration, and patient counseling

Clinical Considerations for Nurses When Administering DARZALEX FASPRO™: Part II (Live Simulated Demo)

Janssen Oncology (DARZALEX)

The following presentation consists of a live simulated demonstration of the administration of DARZALEX FASPRO™ using a surrogate abdomen. This demonstration will discuss preparation, administration, handling, and storage of DARZALEX FASPRO™.

Thursday, September 17, 2020
9–10 am EST

Immunotherapy for Multiple Myeloma: From Antibodies to CAR T-Cell Therapy

1 Contact Hour

REGISTER HERE: https://education.redmeded.com/a/RJXBAM

Jointly provided by the Multiple Myeloma Research Foundation, Purdue University Continuing Nursing Education, and RedMedEd. Support for this activity has been provided through educational grants from Bristol Myers Squibb; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; Karyopharm Therapeutics, Inc.; and Sanofi Genzyme.

Multiple myeloma remains incurable, but the number and type of treatments continue to expand rapidly. A development that holds particular promise for patients with relapsed/refractory myeloma is the emergence of immunotherapy options such as antibody-based therapies, bispecific T-cell engagers, and chimeric antigen receptor T–cell therapy. Successful implementation of myeloma immunotherapy into practice, however, requires oncology nurses and advanced practitioners to be current on new and emerging immunotherapeutic agents and strategies. This webcast will provide information on the newest myeloma immunotherapy treatments, including their rationale for use and results from ongoing clinical studies. There is no fee for attending this activity. At the conclusion of the activity, participants must complete an evaluation and credit request. Certificates will be emailed approximately 4 weeks after participation.

Traversing New Terrains In CLL:The Emerging Role Of BTK Inhibitors In The Treatment Landscape
Presented by Creative Educational Concepts (CEC) and supported by an independent educational grant from AstraZeneca.

Let us buy your lunch after the meeting! Receive a GrubHub credit for attending this presentation and 1.0 ANCC credit. This symposium will review the rationale for targeting the B-cell receptor (BCR) pathway in CLL and its role in tumor proliferation. There will also be discussion regarding the latest safety and efficacy data for BTK inhibitors in CLL based on line of therapy, cytogenetics, and other patient-/disease-specific factors, latest guidelines, as well as identification of patients that would derive benefit from BTK inhibitor therapy. Attendees of this virtual symposium will also gain knowledge about the differences between available BTK inhibitors and how to quickly recognize and appropriately manage adverse events that may arise with therapy. The final portion of the presentation will be interactive and focus on applying the latest evidence into clinical practice by discussing CLL/SLL patient cases and the various challenges faced by clinicians managing patients with BTK inhibitors. There will also be discussion on how BTK inhibitor can be of potential benefit for patients at risk or who contract COVID-19.

The Oncology Nursing Guide to Tumor Treating Fields as a Fourth Modality in Cancer Treatment

Understanding the Science and Evidence and Implementing Critical Nursing Roles in Practice

1 Contact Hour

REGISTER HERE: PeerView.com/TTFields-Nursing

This activity is supported by an educational grant from Novocure.

This CNE activity is jointly provided by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education.

While much of cancer therapy development focuses on systemic drugs and the mitigation of associated adverse events, new avenues utilizing innovative multimodal solutions have demonstrated the benefit of efficacy with minimal toxicity in solid tumors. New treatment modalities such as tumor treating fields (TTFields) and innovative combination strategies have emerged and entered into the management of solid tumors.

This CNE-accredited web broadcast will feature a review of the cutting-edge advancements in cancer devices, as well as expert insights and case discussions on the appropriate care strategies for patients being treated with new modalities like TTFields therapy. And, the expert panel will review key safety and efficacy evidence on innovative and emerging multimodal strategies for the treatment of GBM, MPM, NSCLC, pancreatic cancer, and other GU and GI tumors.

Three Key Reasons to Attend

1. Hear about emerging multimodal strategies with TTFields that are set to improve the management of challenging solid tumors.

2. Learn care strategies to minimize and manage AEs associated with TTFields and maximize quality of life for patients with cancer.
3. Get the latest evidence on TTFields therapy in the management of GBM and MPM.

_The Oncology Nursing Guide to Tumor Treating Fields as a Fourth Modality in Cancer Treatment: Understanding the Science & Evidence & Implementing Critical Nursing Roles in Practice_

**REGISTER HERE:** PeerView.com/TTFields-Nursing
PVI, Medical Learning Institute
This activity is supported by an educational grant from Novocure.

5–6 pm EST

_A Case-based Discussion on Improving Outcomes in Patients With Newly-Diagnosed secondary AML_

**REGISTER HERE:** [https://www.surveymonkey.com/r/2020ONS](https://www.surveymonkey.com/r/2020ONS)
Jazz Pharmaceuticals

- t-AML and AML-MRC: Presentation, risks, and clinical considerations
- Treatment for adults with newly diagnosed t-AML or AML-MRC
- Key issues for nurses: Managing AML treatment complications and supporting the patient through counseling and education
- Critical decision points in care: Dialog on the essential role of the nurse

_Emerging Treatment and Management Strategies for Myelodysplastic Syndromes and Myeloid Malignancies_

1.5 Contact Hours
Aplastic Anemia & MDS International Foundation.

This activity is supported by an educational grant from Bristol Myers Squibb.

The symposium faculty will discuss the latest developments in diagnosing and treating myeloid malignancies; emerging treatment options for low-risk MDS, high-risk MDS, and secondary AML; disease management for chronic anemia, side effects and treatment adherence; psychosocial considerations and palliative care to improve the quality of life for this patient population. Case studies will be used to illustrate treatment decision-making and therapeutic challenges. Upon completion of this activity the participants should be able to:

- Explain the role of genetic testing in diagnosing, stratifying and treating myeloid malignancies;
- Identify emerging treatment options for patients with low-risk MDS, high-risk MDS, and secondary AML;
• Analyze the nurse’s role in managing treatment for myeloid malignancies based on clinical presentations, diagnostic workups, transfusion dependence, comorbidities;

• Discuss the nurse’s role in collaboration with other disciplines in addressing treatment goals and providing patient education to improve outcomes.

Visit the RTP archived webinars slide site to review related topics presented in conjunction with the ONS Bridge Conference.